Why Sonnet BioTherapeutics (SONN) Shares Are Down 19% Today
Why Sonnet BioTherapeutics (SONN) Shares Are Down 19% Today
The reverse split will also proportionately adjust warrants, stock options and equity incentive plans. Per Sonnet, stockholders approved this action on September 12.Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) shares are trading lower by 19.9% to 72 cents Wednesday afternoon after the company announced a 1-for-8 reverse stock split.
Sonnet BioTherapeutics Holdings公司（納斯達克：SONN）股價週三下跌了19.9%，至72美分，下午在公司宣佈進行1比8的股票合併後。
What Else: Sonnet BioTherapeutics says the reverse stock split will be effective for trading on September 30. The move is aimed at meeting Nasdaq's $1.00 minimum bid price requirement.
另外：Sonnet BioTherapeutics表示，股票的合併將於9月30日開始交易。此舉旨在滿足納斯達克1.00美元的最低競價要求。
The reverse split will reduce the company's outstanding shares from 5.2 million to approximately 650,300, while maintaining the same par value and authorized share count.
該股票的合併將把公司的流通股份從520萬股減少至約65,030股，同時保持相同的面值和授權股份數目。
The reverse split will also proportionately adjust warrants, stock options and equity incentive plans. Per Sonnet, stockholders approved this action on September 12.
股票的合併還將按比例調整權證、股票期權和股權激勵計劃。據Sonnet稱，股東已於9月12日批准了此舉。
Read Also: Fed's Favorite Inflation Data Friday Could Sway November Interest Rate Cut Odds
也可閱讀：聯儲局的最喜歡通脹數據可能影響11月的減息幾率
Should I Sell My SONN Stock?
我應該賣出我的SONN股票嗎？
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
賣出或持有股票很大程度上取決於投資者的策略和風險承受能力。短期交易者可能會出售表現優異的股票以鎖定資本收益，而長期投資者可能會在期待股價進一步增長的動盪中保持持有。
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
同樣，願意將損失最小化的交易者可能會出售下跌一定百分比的股票，而長期投資者則可能會將其視爲以折扣價買入更多股票的機會。
Shares of Sonnet BioTherapeutics have lost 72.99% year to date. This compares to the average annual return of -83.32%, meaning the stock has outperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity.
Sonnet BioTherapeutics的股價今年以來下跌了72.99%。這與平均年回報率-83.32%相比，意味着該股票表現優於其歷史平均水平。投資者可以將一支股票的走勢與其歷史表現進行比較，以判斷這是否是正常波動還是潛在的交易機會。
For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.
欲獲取分析工具、圖表數據和獨家股票新聞，請登錄Benzinga PRO。現在免費試用。
SONN has a 52-week high of $3.05 and a 52-week low of $0.62.
SONN的52周最高價爲$3.05，52周最低價爲$0.62。
譯文內容由第三人軟體翻譯。
